BLUJEPA Trademark

Trademark Overview


On Thursday, August 10, 2023, a trademark application was filed for BLUJEPA with the United States Patent and Trademark Office. The USPTO has given the BLUJEPA trademark a serial number of 98126258. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, August 6, 2024. This trademark is owned by Glaxo Group Limited. The BLUJEPA trademark is filed in the Pharmaceutical Products category with the following description:

Vaccines; Anti-infectives; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the treatment of bacterial diseases and infections
blujepa

General Information


Serial Number98126258
Word MarkBLUJEPA
Filing DateThursday, August 10, 2023
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, August 6, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, August 6, 2024

Trademark Statements


Description of MarkThe mark consists of the word "BLUJEPA" to the left of a stylized bow and arrow.
Goods and ServicesVaccines; Anti-infectives; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the treatment of bacterial diseases and infections
Indication of Colors claimedColor is not claimed as a feature of the mark.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSunday, September 10, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressStevenage SG12NY
GB

Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressStevenage SG12NY
GB

Trademark Events


Event DateEvent Description
Monday, August 14, 2023NEW APPLICATION ENTERED
Sunday, September 10, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, March 25, 2024ASSIGNED TO EXAMINER
Monday, April 1, 2024LETTER OF SUSPENSION E-MAILED
Tuesday, September 12, 2023NOTICE OF DESIGN SEARCH CODE E-MAILED
Thursday, November 9, 2023TEAS VOLUNTARY AMENDMENT RECEIVED
Monday, April 1, 2024SUSPENSION LETTER WRITTEN
Tuesday, June 18, 2024TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Monday, April 1, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, April 1, 2024ASSIGNED TO LIE
Thursday, June 20, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, July 1, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 17, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 6, 2024PUBLISHED FOR OPPOSITION
Tuesday, August 6, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, June 20, 2024TEAS/EMAIL CORRESPONDENCE ENTERED